TRAWS PHARMA, INC.
Last · NasdaqCM$0.4012-0.0089 (-2.17%)close · yahoo · 16h ago
Market cap$6.17M15.4M sh
P/E · TTM-0.2fwd -0.2 · eps -1.71 · loss
Beta1.53vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.3921$3.23
Volume148.8Ksession
| Revenue | $2.8M |
|---|---|
| Operating income | $-17.9M |
| Net income | $6.9M |
| Free cash flow | $-20.8M |
| Operating margin | -640.7% |
| Net margin | 246.1% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-04-15
- Sbc Revenue High
- Operating Cf Burn
- Cash Conversion Weak
- Cash Runway Low
- Current Ratio Low
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 26.1%
- Operating Cf Burn — Negative operating cash flow
- Cash Conversion Weak — Cash conversion (CFO/Rev) -651.8%
- Cash Runway Low — Cash runway ~0.2 years
- Current Ratio Low — Current ratio 0.72
- Rd Intensity High — R&D/Revenue 435.2%
Press & signals
- GlobeNewswire
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
- GlobeNewswire
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Documents
FormReporting forFiledFlags